These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 24966582)

  • 1. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.
    Lonardo A; Adinolfi LE; Restivo L; Ballestri S; Romagnoli D; Baldelli E; Nascimbeni F; Loria P
    World J Gastroenterol; 2014 Jun; 20(23):7089-103. PubMed ID: 24966582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic alterations and hepatitis C: From bench to bedside.
    Chang ML
    World J Gastroenterol; 2016 Jan; 22(4):1461-76. PubMed ID: 26819514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype 3 Infection: The Last Stand of Hepatitis C Virus.
    Chan A; Patel K; Naggie S
    Drugs; 2017 Feb; 77(2):131-144. PubMed ID: 28074358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ; Lee SD
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver.
    Ryan MC; Desmond PV; Slavin JL; Congiu M
    J Viral Hepat; 2011 Jan; 18(1):53-60. PubMed ID: 20196803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?].
    Lonardo A; Loria P; Adinolfi LE; Andreana A; Ruggiero G; Carulli N
    Ann Ital Med Int; 2005; 20(1):10-22. PubMed ID: 15859390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
    Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species.
    Fujinaga H; Tsutsumi T; Yotsuyanagi H; Moriya K; Koike K
    Oncology; 2011; 81 Suppl 1():11-7. PubMed ID: 22212930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus diversity and hepatic steatosis.
    Roingeard P
    J Viral Hepat; 2013 Feb; 20(2):77-84. PubMed ID: 23301542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of steatosis in hepatitis C virus infection.
    Adinolfi LE; Restivo L; Marrone A
    Expert Rev Gastroenterol Hepatol; 2013 Mar; 7(3):205-13. PubMed ID: 23445230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.
    Adinolfi LE; Rinaldi L; Guerrera B; Restivo L; Marrone A; Giordano M; Zampino R
    Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27231906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation.
    Conti B; Porcu C; Viscomi C; Minutolo A; Costantini S; Corazzari M; Iannucci G; Barbaro B; Balsano C
    Oncotarget; 2016 Dec; 7(51):84575-84586. PubMed ID: 27661118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid metabolism and liver disease in hepatitis C viral infection.
    Koike K; Tsutsumi T; Yotsuyanagi H; Moriya K
    Oncology; 2010 Jul; 78 Suppl 1():24-30. PubMed ID: 20616580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections.
    Patra T; Sasaki R; Meyer K; Ray RB; Ray R
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models in the study of hepatitis C virus-associated liver pathologies.
    Lerat H; Higgs M; Pawlotsky JM
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):341-52. PubMed ID: 21651352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of HCV genetic differences on pathobiology of disease.
    Ripoli M; Pazienza V
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):747-59. PubMed ID: 21905784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Steatosis and hepatitis C].
    Testino G
    Recenti Prog Med; 2005 Dec; 96(12):621-33; quiz 654. PubMed ID: 16496750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus infection and liver steatosis.
    Ramalho F
    Antiviral Res; 2003 Oct; 60(2):125-7. PubMed ID: 14638408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.
    Rockey DC; Friedman SL
    Gastroenterology; 2021 Apr; 160(5):1502-1520.e1. PubMed ID: 33529675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
    PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.